Browse > Article
http://dx.doi.org/10.13160/ricns.2015.8.3.176

3D-QSAR Studies of 8-Substituted-2-aryl-5-alkylaminoquinolines as Corticotropin-releasing Factor-1 Receptor Antagonists  

Nagarajan, Santhosh Kumar (Department of Bioinformatics, School of Bioengineering, SRM University)
Madhavan, Thirumurthy (Department of Bioinformatics, School of Bioengineering, SRM University)
Publication Information
Journal of Integrative Natural Science / v.8, no.3, 2015 , pp. 176-183 More about this Journal
Abstract
Corticotropin-releasing actor receptors (CRFRs) activates the hypothalamic pituitary adrenal axis, one of the 2 parts of the fight or flight response to stress. Increased CRH production has is associated with Alzheimer's disease and major depression and hypoglycemia. In this study, we report the important structural and chemical parameters for CRFR inhibitors using the derivatives of 8-substituted-2-aryl-5-alkylaminoquinolines. A 3D QSAR study, Comparative molecular field analysis (CoMFA) was performed. The best predictions were obtained for the best CoMFA model with a $q^2$ of 0.607 with 6 components and $r^2$ of 0.991. The statistical parameters from the generated CoMFA models indicated that the data are well fitted and have high predictive ability. The contour map resulted from the CoMFA models might be helpful in the future designing of novel and more potent CRFR derivatives.
Keywords
3D-QSAR; CoMFA; CRFR; CRHR;
Citations & Related Records
연도 인용수 순위
  • Reference
1 B. P. Grone and K. P. Maruska, "A second corticotropin-releasing hormone gene (CRH2) is conserved across vertebrate classes and expressed in the hindbrain of a basal neopterygian fish, the spotted gar", J. Comp. Neurol., Vol. 523, pp. 1125-1143, 2015.   DOI   ScienceOn
2 R. L. Hauger, D. E. Grigoriadis, M. F. Dallman, P. M. Plotsky, W. W. Vale, and F. M. Dautzenberg, "International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands", Pharmacol. Rev., Vol. 55, pp. 21-26, 2003.   DOI   ScienceOn
3 N. Sato, K. Takagi, T. Suzuki, Y. Miki, S. Tanaka, S. Nagase, H. Warita, S. Fukudo, F. Sato, H. Sasano, and K. Ito, "Immunolocalization of corticotropin-releasing Hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor", Int. J. Gynecol. Cancer, Vol. 24, pp. 1549-1557, 2014.   DOI   ScienceOn
4 F. Stamatelou, E. Deligeoroglou, N. Vrachnis, S. Iliodromiti, Z. Iliodromiti, S. Sifakis, G. Farmakides, and G. Creatsas, "Corticotropin-releasing hormone and progesterone plasma levels association with the onset and progression of labor", Clin. Exp. Obstet. Gyn., Vol. 40, pp. 568-571, 2013.
5 F. C. Raadsheer, J. J. V. Heerikhuize, P. J. Lucassen, W. J. Hoogendijk, F. J. Tilders, and D. F. Swaab, "Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with alzheimer's disease and depression", Am. J. Psychiat., Vol. 152, pp. 1372-1376, 1995.   DOI   ScienceOn
6 H.-B. Fan, T. Zhang, K. Sun, S.-P. Song, S.-B. Cao, H.-L. Zhang, and W. Shen, "Corticotropin-releasing factor mediates bone cancer induced pain through neuronal activation in rat spinal cord", Tumor Biol., pp. 1-7, 2015.
7 V. Coric, H. H. Feldman, D. A. Oren, A. Shekhar, J. Pultz, R. C. Dockens, X. Wu, K. A. Gentile, S.-P. Huang, E. Emison, T. Delmonte, B. B. D'Souza, D. L. Zimbroff, J. A. Grebb, A. W. Goddard, and E. G. Stock., "Multicenter, randomized, doubleblind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder." Depress. Anxiety, Vol. 27, pp. 417-425, 2010.   DOI   ScienceOn
8 E. M. Jutkiewicz, S. K. Wood, H. Houshyar, L.-W. Hsin, K. C. Rice, and J. H. Woods, "The effects of CRF antagonists, antalarmin, CP154, 526, LWH234, and R121919, in the forced swim test and on swiminduced increases in adrenocorticotropin in rats" Psychopharmacology, Vol. 180, pp. 215-223, 2005.   DOI
9 B. Binneman, D. Feltner, S. Kolluri, Y. Shi, R. Qiu, and T. Stiger, "A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression", Am. J. Psychiat., Vol. 165, pp. 617-620, 2008.   DOI   ScienceOn
10 R. Pastor, C. S. McKinnon, A. C. Scibelli, S. Burkhart-Kasch, C. Reed, A. E. Ryabinin, S. C. Coste, M. P. Stenzel-Poore, and T. J. Phillips, "Corticotropin-releasing factor-1 receptor involvement in behavioral neuroadaptation to ethanol: A urocortin1-independent mechanism", P. Natl. Acad. Sci. U.S.A., Vol. 105, pp. 9070-9075, 2008.   DOI   ScienceOn
11 K. Takeda, T. Terauchi, M. Hashizume, K. Shikata, R. Taguchi, K. Murata-Tai, M. Fujisawa, Y. Takahashi, K. Shin, M. Ino, H. Shibata, and M. Yonaga, "Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists", Bioorgan. Med. Chem., Vol. 20, pp. 6559-6578, 2012.   DOI   ScienceOn
12 S. J. Cho and A. Tropsha, "Cross-validated R2-guided region selection for comparative molecular field analysis: A simple method to achieve consistent results", J. Med. Chem., Vol. 37, pp. 1060-1066, 1995.
13 S. Wold, M. Sjostrom, and L. Eriksson, "PLSregression: a basic tool of chemometrics", Chemometr. Intell. Lab., Vol. 58, pp. 109-130, 2001.   DOI   ScienceOn
14 U. Debnath, S. Verma, S. Jain, S. B. Katti, and Y. S. Prabhakar, "Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics", J. Comput. Aid. Mol. Des., Vol. 27, pp. 637-654, 2013.   DOI   ScienceOn
15 D. Fernandez, J. Ortega-Castro, and J. Frau, "Human farnesyl pyrophosphate synthase inhibition by nitrogen bisphosphonates: A 3D-QSAR study", J. Comput. Aid. Mol. Des., Vol. 27, pp. 739-754, 2013.   DOI   ScienceOn